{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:00:58Z","timestamp":1777564858300,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX000523"],"award-info":[{"award-number":["I01BX000523"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12918-018-0603-9","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T13:42:31Z","timestamp":1531834951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice"],"prefix":"10.1186","volume":"12","author":[{"given":"Guan-Sheng","family":"Liu","sequence":"first","affiliation":[]},{"given":"Richard","family":"Ballweg","sequence":"additional","affiliation":[]},{"given":"Alan","family":"Ashbaugh","sequence":"additional","affiliation":[]},{"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Joseph","family":"Facciolo","sequence":"additional","affiliation":[]},{"given":"Melanie T.","family":"Cushion","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-6279","authenticated-orcid":false,"given":"Tongli","family":"Zhang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"issue":"9","key":"603_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/14787210.2017.1364991","volume":"15","author":"YS Huang","year":"2017","unstructured":"Huang YS, Yang JJ, Lee NY, Chen GJ, Ko WC, Sun HY, Hung CC. Treatment of pneumocystis jirovecii pneumonia in HIV-infected patients: a review. Expert Rev Anti-Infect Ther. 2017;15(9):873\u201392.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"35","key":"603_CR2","doi-asserted-by":"crossref","first-page":"59729","DOI":"10.18632\/oncotarget.19927","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Su L, Jiang SJ, Qu H. Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. Oncotarget. 2017;8(35):59729\u201339.","journal-title":"Oncotarget"},{"issue":"4","key":"603_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/jeu.12385","volume":"64","author":"A Luraschi","year":"2017","unstructured":"Luraschi A, Cisse OH, Pagni M, Hauser PM. Identification and functional ascertainment of the pneumocystis jirovecii potential drug targets Gsc1 and Kre6 involved in glucan synthesis. J Eukaryot Microbiol. 2017;64(4):481\u201390.","journal-title":"J Eukaryot Microbiol"},{"issue":"4","key":"603_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1086\/526778","volume":"46","author":"PD Walzer","year":"2008","unstructured":"Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46(4):625\u201333.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"603_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1513\/pats.201009-062WR","volume":"8","author":"L Huang","year":"2011","unstructured":"Huang L, Cattamanchi A, Davis JL, den Boon S, Kovacs J, Meshnick S, Miller RF, Walzer PD, Worodria W, Masur H, et al. HIV-associated pneumocystis pneumonia. Proc Am Thorac Soc. 2011;8(3):294\u2013300.","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"603_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3201\/eid1901.120140","volume":"19","author":"M Rabodonirina","year":"2013","unstructured":"Rabodonirina M, Vaillant L, Taffe P, Nahimana A, Gillibert RP, Vanhems P, Hauser PM. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia. Emerg Infect Dis. 2013;19(1):21\u20138. quiz 186","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"603_CR7","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1128\/AAC.48.11.4301-4305.2004","volume":"48","author":"A Nahimana","year":"2004","unstructured":"Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004;48(11):4301\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"603_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1574-6968.2006.00118.x","volume":"256","author":"PM Hauser","year":"2006","unstructured":"Hauser PM, Macreadie IG. Isolation of the pneumocystis carinii dihydrofolate synthase gene and functional complementation in Saccharomyces cerevisiae. FEMS Microbiol Lett. 2006;256(2):244\u201350.","journal-title":"FEMS Microbiol Lett"},{"issue":"4","key":"603_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1128\/EC.00309-08","volume":"8","author":"JM Beck","year":"2009","unstructured":"Beck JM, Cushion MT. Pneumocystis workshop: 10th anniversary summary. Eukaryot Cell. 2009;8(4):446\u201360.","journal-title":"Eukaryot Cell"},{"issue":"3","key":"603_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/jeu.12034","volume":"60","author":"LM Weiss","year":"2013","unstructured":"Weiss LM, Cushion MT, Didier E, Xiao L, Marciano-Cabral F, Sinai AP, Matos O, Calderon EJ, Kaneshiro ES. The 12th international workshops on opportunistic Protists (IWOP-12). J Eukaryot Microbiol. 2013;60(3):298\u2013308.","journal-title":"J Eukaryot Microbiol"},{"issue":"5","key":"603_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/jeu.12221","volume":"62","author":"EJ Calderon","year":"2015","unstructured":"Calderon EJ, Cushion MT, Xiao L, Lorenzo-Morales J, Matos O, Kaneshiro ES, Weiss LM. The 13th international workshops on opportunistic Protists (IWOP13). J Eukaryot Microbiol. 2015;62(5):701\u20139.","journal-title":"J Eukaryot Microbiol"},{"issue":"3","key":"603_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1054\/drup.2000.0146","volume":"3","author":"O Skold","year":"2000","unstructured":"Skold O. Sulfonamide resistance: mechanisms and trends. Drug Resist Updat. 2000;3(3):155\u201360.","journal-title":"Drug Resist Updat"},{"issue":"10","key":"603_CR13","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3201\/eid1010.030994","volume":"10","author":"L Huang","year":"2004","unstructured":"Huang L, Crothers K, Atzori C, Benfield T, Miller R, Rabodonirina M, Helweg-Larsen J. Dihydropteroate synthase gene mutations in pneumocystis and sulfa resistance. Emerg Infect Dis. 2004;10(10):1721\u20138.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"603_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1086\/378239","volume":"188","author":"A Nahimana","year":"2003","unstructured":"Nahimana A, Rabodonirina M, Zanetti G, Meneau I, Francioli P, Bille J, Hauser PM. Association between a specific pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine\/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis. 2003;188(7):1017\u201323.","journal-title":"J Infect Dis"},{"issue":"Suppl","key":"603_CR15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1550-7408.2003.tb00673.x","volume":"50","author":"A Nahimana","year":"2003","unstructured":"Nahimana A, Rabodonirina M, Francioli P, Bille J, Hauser PM. Pneumocystis jirovecii dihydrofolate reductase polymorphisms associated with failure of prophylaxis. J Eukaryot Microbiol. 2003;50(Suppl):656\u20137.","journal-title":"J Eukaryot Microbiol"},{"key":"603_CR16","first-page":"123","volume":"2","author":"JG Castro","year":"2010","unstructured":"Castro JG, Morrison-Bryant M. Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. HIV AIDS (Auckl). 2010;2:123\u201334.","journal-title":"HIV AIDS (Auckl)"},{"issue":"8","key":"603_CR17","first-page":"563","volume":"12","author":"RJ Artymowicz","year":"1993","unstructured":"Artymowicz RJ, James VE. Atovaquone: a new antipneumocystis agent. Clin Pharm. 1993;12(8):563\u201370.","journal-title":"Clin Pharm"},{"issue":"6858","key":"603_CR18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/35101544","volume":"413","author":"F Schlunzen","year":"2001","unstructured":"Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F. Structural basis for the interaction of antibiotics with the peptidyl transferase Centre in eubacteria. Nature. 2001;413(6858):814\u201321.","journal-title":"Nature"},{"issue":"8","key":"603_CR19","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1128\/AAC.42.8.1985","volume":"42","author":"MA Powles","year":"1998","unstructured":"Powles MA, Liberator P, Anderson J, Karkhanis Y, Dropinski JF, Bouffard FA, Balkovec JM, Fujioka H, Aikawa M, McFadden D, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of pneumocystis carinii. Antimicrob Agents Chemother. 1998;42(8):1985\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"603_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/jac\/dkg117","volume":"51","author":"V Letscher-Bru","year":"2003","unstructured":"Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother. 2003;51(3):513\u201321.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"603_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1130-1406(09)70004-X","volume":"26","author":"A Espinel-Ingroff","year":"2009","unstructured":"Espinel-Ingroff A. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009;26(1):15\u201322.","journal-title":"Rev Iberoam Micol"},{"key":"603_CR22","volume-title":"Foye's principles of medicinal chemistry","author":"WO Foye","year":"2013","unstructured":"Foye WO, Lemke TL, Williams DA. Foye's principles of medicinal chemistry. 7th ed. Philadelphia: Wolters Kluwer Health\/Lippincott Williams & Wilkins; 2013.","edition":"7"},{"issue":"6","key":"603_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00151829-200403060-00005","volume":"3","author":"N Patel","year":"2004","unstructured":"Patel N, Koziel H. Pneumocystis jiroveci pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat Respir Med. 2004;3(6):381\u201397.","journal-title":"Treat Respir Med"},{"issue":"11\u201312","key":"603_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3109\/00365540903214256","volume":"41","author":"M Thomas","year":"2009","unstructured":"Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg\/kg\/day-sulfamethoxazole 50 mg\/kg\/day for pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;41(11\u201312):862\u20138.","journal-title":"Scand J Infect Dis"},{"issue":"8","key":"603_CR25","doi-asserted-by":"publisher","first-page":"e70619","DOI":"10.1371\/journal.pone.0070619","volume":"8","author":"ML Lobo","year":"2013","unstructured":"Lobo ML, Esteves F, de Sousa B, Cardoso F, Cushion MT, Antunes F, Matos O. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. PLoS One. 2013;8(8):e70619.","journal-title":"PLoS One"},{"issue":"23\u201324","key":"603_CR26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.drudis.2011.10.001","volume":"16","author":"BM Agoram","year":"2011","unstructured":"Agoram BM, Demin O. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. Drug Discov Today. 2011;16(23\u201324):1031\u20136.","journal-title":"Drug Discov Today"},{"key":"603_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.csbj.2016.09.002","volume":"14","author":"VR Knight-Schrijver","year":"2016","unstructured":"Knight-Schrijver VR, Chelliah V, Cucurull-Sanchez L, Le Novere N. The promises of quantitative systems pharmacology modelling for drug development. Comput Struct Biotechnol J. 2016;14:363\u201370.","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"603_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1128\/AAC.01567-12","volume":"57","author":"MA Lyons","year":"2013","unstructured":"Lyons MA, Reisfeld B, Yang RS, Lenaerts AJ. A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob Agents Chemother. 2013;57(4):1763\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"603_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10928-014-9380-2","volume":"41","author":"MA Lyons","year":"2014","unstructured":"Lyons MA. Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment. J Pharmacokinet Pharmacodyn. 2014;41(6):613\u201323.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"603_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10928-015-9419-z","volume":"42","author":"MA Lyons","year":"2015","unstructured":"Lyons MA, Lenaerts AJ. Computational pharmacokinetics\/pharmacodynamics of rifampin in a mouse tuberculosis infection model. J Pharmacokinet Pharmacodyn. 2015;42(4):375\u201389.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"603_CR31","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1002\/psp4.20","volume":"4","author":"MC Peterson","year":"2015","unstructured":"Peterson MC, Riggs MM. FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment? CPT Pharmacometrics Syst Pharmacol. 2015;4(3):e00020.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"603_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/jac\/dkv416","volume":"71","author":"O Clewe","year":"2016","unstructured":"Clewe O, Aulin L, Hu Y, Coates AR, Simonsson US. A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro. J Antimicrob Chemother. 2016;71(4):964\u201374.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"603_CR33","doi-asserted-by":"publisher","first-page":"e8524","DOI":"10.1371\/journal.pone.0008524","volume":"5","author":"MT Cushion","year":"2010","unstructured":"Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One. 2010;5(1):e8524.","journal-title":"PLoS One"},{"issue":"7","key":"603_CR34","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1128\/AAC.00126-06","volume":"50","author":"MT Cushion","year":"2006","unstructured":"Cushion MT, Walzer PD, Ashbaugh A, Rebholz S, Brubaker R, Vanden Eynde JJ, Mayence A, Huang TL. In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against pneumocystis pneumonia in mice. Antimicrob Agents Chemother. 2006;50(7):2337\u201343.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"603_CR35","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1128\/AAC.00507-06","volume":"50","author":"T Gumbo","year":"2006","unstructured":"Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, Louie A. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother. 2006;50(11):3695\u2013700.","journal-title":"Antimicrob Agents Chemother"},{"key":"603_CR36","doi-asserted-by":"crossref","unstructured":"Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ. Pharmacological basis of CD101 efficacy: exposure shape matters. Antimicrob Agents Chemother. 2017;61(11)","DOI":"10.1128\/AAC.00758-17"},{"key":"603_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fphar.2014.00247","volume":"5","author":"TA Leil","year":"2014","unstructured":"Leil TA, Bertz R. Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. Front Pharmacol. 2014;5:247.","journal-title":"Front Pharmacol"},{"key":"603_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fphar.2015.00129","volume":"6","author":"TA Leil","year":"2015","unstructured":"Leil TA, Ermakov S. Editorial: the emerging discipline of quantitative systems pharmacology. Front Pharmacol. 2015;6:129.","journal-title":"Front Pharmacol"},{"issue":"2","key":"603_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/0091270007311111","volume":"48","author":"Y Wang","year":"2008","unstructured":"Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol. 2008;48(2):146\u201356.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"603_CR40","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","volume":"54","author":"D Andes","year":"2010","unstructured":"Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54(6):2497\u2013506.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"603_CR41","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1128\/AAC.28.6.761","volume":"28","author":"M Misiek","year":"1985","unstructured":"Misiek M, Buck RE, Pursiano TA, Chisholm DR, Tsai YH, Price KE, Leitner F. Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim. Antimicrob Agents Chemother. 1985;28(6):761\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"603_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1128\/AAC.01061-07","volume":"52","author":"D Andes","year":"2008","unstructured":"Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52(2):539\u201350.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"603_CR43","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1128\/AAC.41.11.2339","volume":"41","author":"R Hajdu","year":"1997","unstructured":"Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997;41(11):2339\u201344.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"603_CR44","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1128\/IAI.71.9.5360-5363.2003","volume":"71","author":"CR Icenhour","year":"2003","unstructured":"Icenhour CR, Kottom TJ, Limper AH. Evidence for a melanin cell wall component in pneumocystis carinii. Infect Immun. 2003;71(9):5360\u20133.","journal-title":"Infect Immun"}],"updated-by":[{"DOI":"10.1186\/s12918-019-0708-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000}}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-018-0603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12918-018-0603-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-018-0603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T10:51:43Z","timestamp":1589539903000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/s12918-018-0603-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/s12918-018-0603-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12918-019-0708-9","asserted-by":"object"}]},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"It was highlighted that the original article [1] contained errors in the figures and their legends and by extension the in-text figure citations. This Corrections article shows the correct figures and correct figure legends.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal protocols used for this study were reviewed and approved by the University of Cincinnati\u2019s IACUC committee and the Cincinnati Veterans Affairs Medical Center IACUC; protocols UC 12\u201305\u201303-01 and ACORP#15\u201302\u201325-01, respectively. Both committees adhere to the 8th edition of the \u201c<i>Guide for the Care and Use of Laboratory Animals<\/i>\u201d and both are AAALAC accredited.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"77"}}